
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is a preclinical stage biotechnology company that leverages its AI-guided drug discovery platform to develop precision antibodies, showing significant potential with near-complete Activin E inhibition and favorable safety profiles compared to competitors. Key intellectual property protection and fundraising for research, development, and regulatory processes are potential factors for the company's future success, which may depend on its progress and clinical validation of its development programs.
Bears say
iBio is a preclinical biotech company that faces significant competition and has additional risks related to its intellectual property and therapeutic products. With no products currently generating revenue, the company will likely need to raise additional funds in the future, which could involve dilution or restrictive covenants. Overall, the company's risky position and lack of stability in terms of revenue generation make it a risky investment for analysts.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares